Goldman Sachs Sticks to Its Buy Rating for Bayer (0P6S)
In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Bayer, with a price target of €54.50.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Quigley covers the Healthcare sector, focusing on stocks such as Bayer, Novo Nordisk, and Roche Holding AG. According to TipRanks, Quigley has an average return of -6.4% and a 41.61% success rate on recommended stocks.
In addition to Goldman Sachs, Bayer also received a Buy from Kepler Capital ‘s Christian Faitz in a report issued on January 26. However, yesterday, TipRanks – OpenAI reiterated a Hold rating on Bayer (LSE: 0P6S).
The company has a one-year high of €46.74 and a one-year low of €18.38. Currently, Bayer has an average volume of 3.54M.
Read More on GB:0P6S:
Disclaimer & DisclosureReport an Issue
- Bayer investing over C$45M to build canola research, development facility
- Bayer, Vanderbilt University Medical Center enter five-year collaboration
- Bayer ‘welcomes’ Supreme Court review of Durnell litigation
- U.S. Supreme Court to hear Bayer’s appeal of Roundup lawsuits, Bloomberg says
- Bayer to acquire AT-01 and AT-05 from Attralus, terms undisclosed
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.